The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for the treatment of schizophrenia in adults.
About Schizophrenia:
It is a chronic, severe mental disorderthat affects the way a person thinks, acts, expresses emotions, perceives reality, and relates to others.
It mostly affects young adultsin the productive age group.
One in every 100 people experiences schizophrenia and men are twice as likely to develop this condition as compared to women.
Symptoms of Schizophrenia:
It can differ from person to person, but they generally fall into three main categories: psychotic, negative, and cognitive.
Psychotic symptoms include Hallucinations, Delusions, thought disorder, Movement disorder.
Negative symptoms include loss of motivation, loss of interest or enjoyment in daily activities, withdrawal from social life, difficulty showing emotions, and difficulty functioning normally.
Cognitive symptoms include problems in attention, concentration, and memory.
Treatment:
Though there is no cure for schizophrenia, a variety of antipsychotic medications are effective in reducing the psychotic symptoms present in the acute phase of the illness.
Psychological treatments such as cognitive behavioral therapy or supportive psychotherapy may reduce symptoms and enhance function.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
